Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high-fat diet
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd..
Monoacylglycerol O-acyltransferase 2 (MGAT2) is one of the key enzymes responsible for triglyceride (TG) re-synthesis in the small intestine. We have previously demonstrated that pharmacological inhibition of MGAT2 has beneficial effects on obesity and metabolic disorders in mice. Here, we further investigate the effects of MGAT2 inhibition on (a) fat-induced gut peptide release and fat intake in normal mice and (b) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB). CpdB inhibited elevation of plasma TG in mice challenged with an oil-supplemented liquid meal. Oil challenge stimulated the secretion of two gut anorectic hormones (peptide tyrosine-tyrosine and glucagon-like peptide-1) into the bloodstream, and these responses were augmented in mice pretreated with CpdB. In a two-choice test using an HFD and a low-fat diet, CpdB selectively inhibited intake of the HFD in normal mice. Administration of CpdB to HFD-fed ob/ob mice for 5 weeks suppressed food intake and body weight gain and inhibited elevation of glycated hemoglobin. These results indicate that pharmacological MGAT2 inhibition modulates fat-induced gut peptide release and fat intake in normal mice and improves obesity and diabetes in HFD-fed ob/ob mice and thus may have potential for development into a treatment of obesity and its related metabolic diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
FEBS open bio - 10(2020), 3 vom: 20. März, Seite 316-326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mochida, Taisuke [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.07.2021 Date Revised 12.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/2211-5463.12778 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304382000 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304382000 | ||
| 003 | DE-627 | ||
| 005 | 20231225114850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/2211-5463.12778 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1014.xml |
| 035 | |a (DE-627)NLM304382000 | ||
| 035 | |a (NLM)31837122 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mochida, Taisuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high-fat diet |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.07.2021 | ||
| 500 | |a Date Revised 12.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. | ||
| 520 | |a Monoacylglycerol O-acyltransferase 2 (MGAT2) is one of the key enzymes responsible for triglyceride (TG) re-synthesis in the small intestine. We have previously demonstrated that pharmacological inhibition of MGAT2 has beneficial effects on obesity and metabolic disorders in mice. Here, we further investigate the effects of MGAT2 inhibition on (a) fat-induced gut peptide release and fat intake in normal mice and (b) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB). CpdB inhibited elevation of plasma TG in mice challenged with an oil-supplemented liquid meal. Oil challenge stimulated the secretion of two gut anorectic hormones (peptide tyrosine-tyrosine and glucagon-like peptide-1) into the bloodstream, and these responses were augmented in mice pretreated with CpdB. In a two-choice test using an HFD and a low-fat diet, CpdB selectively inhibited intake of the HFD in normal mice. Administration of CpdB to HFD-fed ob/ob mice for 5 weeks suppressed food intake and body weight gain and inhibited elevation of glycated hemoglobin. These results indicate that pharmacological MGAT2 inhibition modulates fat-induced gut peptide release and fat intake in normal mice and improves obesity and diabetes in HFD-fed ob/ob mice and thus may have potential for development into a treatment of obesity and its related metabolic diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MGAT2 | |
| 650 | 4 | |a Monoacylglycerol O-acyltransferase 2 | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a gut hormone | |
| 650 | 4 | |a high-fat diet | |
| 650 | 4 | |a obesity | |
| 650 | 7 | |a Dietary Fats |2 NLM | |
| 650 | 7 | |a Dipeptides |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 650 | 7 | |a tyrosyltyrosine |2 NLM | |
| 650 | 7 | |a 1050-28-8 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Acyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.3.- |2 NLM | |
| 650 | 7 | |a 2-acylglycerol O-acyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.3.1.22 |2 NLM | |
| 700 | 1 | |a Take, Kazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Maki, Toshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakakariya, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Ryutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Kenjiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kitazaki, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takekawa, Shiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t FEBS open bio |d 2011 |g 10(2020), 3 vom: 20. März, Seite 316-326 |w (DE-627)NLM217577113 |x 2211-5463 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:3 |g day:20 |g month:03 |g pages:316-326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/2211-5463.12778 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 3 |b 20 |c 03 |h 316-326 | ||